Intellia Therapeutics, Inc
$13.61
USD
Last updated on --.
24h volume2.21M
24h highest13.7240 USD
24h lowest12.4250 USD
24h Price movement+7.97%
NTLA recent prices
24 Hours
+7.97%+$1.005
30 days
-3.22%-$0.42
60 days
+1.78%+$0.22
90 days
-11.62%-$1.660
Key data
Previous close12.6100 USD
Market cap1.71B USD
Volume2.21M
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-2.8200 USD
Net income (FY)-394.60M USD
Revenue (FY)66.09M USD
Last report dateMay 11, 2026
About Intellia Therapeutics, Inc
HeadquartersCAMBRIDGE
Employees (FY)377.00
Revenue per employee (FY)175.31K USD
Net income per employee (FY)-1.05M USD
Listed onNasdaq
NTLA conversion tables
 |  |
|---|---|
| 0.5 NTLA | 6.807 USD |
| 1 NTLA | 13.61 USD |
| 5 NTLA | 68.07 USD |
| 10 NTLA | 136.15 USD |
| |
|---|---|
| 0.5 USD | 0.036724 NTLA |
| 1 USD | 0.073448 NTLA |
| 5 USD | 0.36724 NTLA |
| 10 USD | 0.73448 NTLA |
More to explore
Trending stock
Trending stock PERP
Trending stock token
FAQ
NTLA is trading at $13.61, +7.97% over the last 24 hours. Track live moves on the price chart at the top of this page.
The NTLA stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. NTLA is currently trading at $13.61, +7.97% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on NTLA price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. NTLA's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from NTLA; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against NTLA's historical range and other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector.
Intellia Therapeutics, Inc's market cap is currently 1.71B USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume2.21M
24h highest13.7240 USD
24h lowest12.4250 USD
24h Price movement+7.97%
Start trade with NTLA Perpetual
Sign up to trade